Replies to post #366360 on Innovation Pharmaceuticals Inc (IPIX)

[attilathehunt]

Nice catch....On slide 14....what is the difference between 5 and 5 (e)? It is also repeated with 10 and 20....what does the "e" stand for?

[Rdunn88]

Why seeing continued studying and development being dangled in press releases is a concern... The focus should be on emergency use and possibly phase 3... Who cares about a 5 to 10 year development plan... The share price will go no place until the "pretend" CEO confirms an actual strategy...

[Lemoncat]

I was hoping for something to come out of it that would apply to the real world and move the share price.

That's why the upcoming trial results are so important. We saw with Remdesivir that robust antiviral activity alone did not translate into great clinical results.

1. Is the dosage we're able to give, enough to elicit a good clinical response? This is why I have said Selectivity Index, which thankfully isn't mentioned here much anymore, is completely useless when you have a systemic dosage ceiling.

2. Does the anti-inflammatory properties of Brilacidin significantly boost clinical performance beyond what we would expect of an antiviral alone? Remdesivir being the anti-viral available for comparison.

Go IPIX!

[L vus]

" Both this dose and pretreatment of brilacidin are not possible when using brilacidin as a therapeutic in the real world. "
My question to use is why can't Brilacidin be both a prophylactic and a therapeutic in the real world?
Thank you for your post.

[wsbc]

An interesting comment from a virologist-friend a few months back related to anti-virals needing to be 100% effective as anti-virals, or they're 100% ineffective.

Requiring an extended dosing period in the COVID trial makes me feel like it's not close to 100% effective as an anti-viral. Concerning? Hopefully the other MOA's help in other ways somehow?

I haven't read through the materials yet, but more POC stuff from Leo is par for the course for this company. Paying himself almost $1M this year alone for what? More tests? 15yrs of this company 'running more tests'. This is what shareholders are getting for their investment? Dilution and testing? Testing that doesn't even apply to the real world nonetheless!

In vitro data presented at ASV 2021 for Alphavirus and Bunyavirus used brilacidin at a concentration of 20µm and included pretreatment of the virus with brilacidin. The concentration of 20µm converts to a dose >1.5 mg/kg (almost 2X the highest single dose used in the ABSSSI P2 trial) while the pretreatment improves the potency of brilacidin. Both this dose and pretreatment of brilacidin are not possible when using brilacidin as a therapeutic in the real world. This is PoC stuff, and I know that investors were not the intended audience, but I was hoping for something to come out of it that would apply to the real world and move the share price.

2 slides seem to be missing from the deck. The slides are numbered 1-21 but there are 19 slides in the PDF. Slide 6 or 7 and 13 are not included.

[frenchbroad]

*Both this dose and pretreatment of brilacidin are not possible when using brilacidin as a therapeutic in the real world.*

Please try to think: where does Briacidin go when you put it in the blood?

For help, the answer starts with every and ends with where.

[Rdunn88]

IPIX's website has all 21 slides in the PDF....

https://www.ipharminc.com/new-events-and-presentations/2021/7/21-american-society-of-virology-annual-meeting


https://static1.squarespace.com/static/5715352e20c647639137f992/t/60f98b02dee5a72cfce0c44e/1626966816579/GMU+ASV+2021+Brilacidin+talk+fv+7.21.21.pdf